Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of the anti-HCV drug sofosbuvir: a preliminary study.

The Journal of antimicrobial chemotherapy - 1 Jun 2018

Cusato Jessica, De Nicolò Amedeo, Boglione Lucio, Favata Fabio, Ariaudo Alessandra, Mornese Pinna Simone, Carcieri Chiara, Guido Federica, Avataneo Valeria, Cariti Giuseppe, Di Perri Giovanni, D'Avolio Antonio

Abstract excerpt

Background: Sofosbuvir is a potent nucleotide HCV NS5B polymerase inhibitor that is also a P-glycoprotein (encoded by the ABCB1 gene) and breast cancer resistance protein (encoded by the ABCG2 gene) substrate. Concerning previous anti-HCV therapies, pharmacogenetics had a significant impact, particularly considering the association of interleukin28B polymorphisms with dual-therapy (ribavirin + pegylated IFN)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP Binding Cassette Transporter, Subfamily B
Share to ATP Binding Cassette Transporter, Subfamily G, Member 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C Antibodies

Share to Hepatitis C, Chronic

Share to Hepatocyte Nuclear Factor 4

Share to Pharmacogenetics

Share to Real-Time Polymerase Chain Reaction

Share to Sofosbuvir

Source

Identifiers

PMID: 29509884
DOI: 10.1093/jac/dky053

Genes

ABCB1
ABCG2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of the anti-HCV drug sofosbuvir: a preliminary study.PMID 29509884Read ↗

The effect of genetic variations on ribavirin pharmacokinetics and treatment response in HCV-4 Egyptian patients receiving sofosbuvir/daclatasvir and ribavirin.Semantic proximity Read ↗

Vitamin D pathway genetic variants are able to influence sofosbuvir and its main metabolite pharmacokinetics in HCV mono-infected patients.Semantic proximity Read ↗

Influence of ABCB11 and HNF4α genes on daclatasvir plasma concentration: preliminary pharmacogenetic data from the Kineti-C study.Semantic proximity Read ↗

Pharmacogenetics of efficacy and safety of HCV treatment in HCV-HIV coinfected patients: significant associations with IL28B and SOCS3 gene variants.Semantic proximity Read ↗

Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C.Semantic proximity Read ↗

Sofosbuvir in the treatment of chronic hepatitis C: new dog, new tricks.Semantic proximity Read ↗

Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure.Semantic proximity Read ↗

The evolution of the therapeutic strategy in hepatitis C: features of sofosbuvir and indications.Semantic proximity Read ↗

Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection.Semantic proximity Read ↗

Pharmacokinetics and pharmacodynamics of sofosbuvir and ledipasvir for the treatment of hepatitis C.Semantic proximity Read ↗

The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients.Semantic proximity Read ↗

LO3 : Safety and efficacy of the combination daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients from the french observational cohort ANRS CO22 hepather*Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.